Liquidia Co. (NASDAQ:LQDA - Get Free Report) insider Rajeev Saggar sold 2,526 shares of the company's stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $11.19, for a total transaction of $28,265.94. Following the completion of the sale, the insider now directly owns 204,857 shares of the company's stock, valued at $2,292,349.83. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Rajeev Saggar also recently made the following trade(s):
- On Monday, October 14th, Rajeev Saggar sold 2,260 shares of Liquidia stock. The shares were sold at an average price of $11.11, for a total value of $25,108.60.
Liquidia Stock Up 1.0 %
NASDAQ:LQDA opened at $11.20 on Wednesday. The firm's fifty day simple moving average is $10.35 and its 200-day simple moving average is $11.83. The stock has a market cap of $855.84 million, a PE ratio of -7.18 and a beta of 0.22. Liquidia Co. has a fifty-two week low of $6.04 and a fifty-two week high of $16.99.
Liquidia (NASDAQ:LQDA - Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. The company had revenue of $3.66 million for the quarter, compared to analyst estimates of $7.92 million. Equities analysts anticipate that Liquidia Co. will post -1.69 earnings per share for the current year.
Institutional Investors Weigh In On Liquidia
Watch this before it gets removed
From Porter & Company | Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
A number of institutional investors and hedge funds have recently modified their holdings of the company. Signaturefd LLC raised its stake in shares of Liquidia by 38,400.0% during the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company's stock worth $100,000 after buying an additional 9,984 shares during the last quarter. DMC Group LLC increased its position in Liquidia by 36.7% during the third quarter. DMC Group LLC now owns 13,883 shares of the company's stock worth $139,000 after buying an additional 3,725 shares in the last quarter. Creative Planning purchased a new position in Liquidia during the third quarter worth $170,000. Sapient Capital LLC acquired a new position in shares of Liquidia in the third quarter worth $1,336,000. Finally, SG Americas Securities LLC acquired a new position in Liquidia in the 3rd quarter valued at about $210,000. Institutional investors and hedge funds own 64.54% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts have weighed in on LQDA shares. Raymond James upgraded Liquidia from an "outperform" rating to a "strong-buy" rating in a research note on Monday, August 19th. Oppenheimer started coverage on shares of Liquidia in a research note on Tuesday, June 25th. They issued a "market perform" rating on the stock. Needham & Company LLC restated a "buy" rating and issued a $25.00 target price on shares of Liquidia in a research note on Monday, August 19th. Lifesci Capital began coverage on shares of Liquidia in a report on Thursday, October 3rd. They issued an "outperform" rating and a $30.00 target price on the stock. Finally, BTIG Research cut their price target on shares of Liquidia from $29.00 to $25.00 and set a "buy" rating for the company in a report on Monday, August 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Liquidia currently has a consensus rating of "Moderate Buy" and an average target price of $24.67.
Check Out Our Latest Report on LQDA
About Liquidia
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
